Singapore Medical Device Regulator: HSA

1. Key takeaways

The competent authority for medical devices in Singapore is the Health Sciences Authority (HSA). The legal foundation is the Health Products Act 2007 (Act No. 15 of 2007) together with its subsidiary legislation, the Health Products (Medical Devices) Regulations 2010. HSA is responsible for product registration, dealer licensing, adverse event surveillance, advertising control and enforcement. Understanding this institutional layout is the starting point of every market entry plan, because it determines who reviews your dossier, who issues your licence, and against whom enforcement action would be taken if something goes wrong after the product reaches the market.

• HSA is the single national regulator for medical devices in Singapore, with no parallel or regional approval body.
• The governing statute is the Health Products Act 2007 (Act No. 15 of 2007), supplemented by the Health Products (Medical Devices) Regulations 2010.
• Operational requirements are set out in the HSA GN and GL guidance series, which are updated frequently and must be checked for the current revision.
• Regulation runs on two parallel tracks: product registration or notification for the device itself, and a Dealer’s Licence for the entity that imports, wholesales or manufactures it.

2. Legal basis

The elements set out below summarise the statutory framework that governs medical devices in Singapore, including the parent Act, its numbering and enactment date, the key operative Parts, the subsidiary regulations and the official guidance documents that applicants work with in practice.

The First Schedule of the Health Products Act lists the categories of health products to which the Act applies, and medical devices are one of those categories. This means that medical devices share the same parent statute as therapeutic products, cosmetics and traditional Chinese medicines, while each category operates under its own set of regulations and guidance documents. In practical terms, you cite the same Act when defining the legal basis of your Singapore submission, but the detailed requirements you follow come from the medical device regulations and the GN/GL guidance series issued under them. Keeping these layers clearly separated is essential when preparing arguments for HSA or responding to queries from other stakeholders.

3. Expert insights

Insight 1: The legal hierarchy has three layers — Act, Regulations and Guidance — and they must not be mixed up. The most common error we encounter in projects is a client citing an HSA guidance document (a GN file) as if it were law, or conversely trying to argue an operational detail directly from the wording of a statutory provision. The Act establishes prohibitions and penalties, the Regulations establish the registration and licensing system, and the GN/GL guidance establishes submission requirements and review standards. The three layers carry different weight and serve different purposes: for penalties look at the Act, for the institutional system look at the Regulations, and for how to actually do something look at the GN. A submission letter or a compliance argument that mixes these layers loses credibility with reviewers and can trigger avoidable queries. When we review a client’s regulatory strategy, we always map every claim in the plan back to the correct layer, so that the eventual dossier speaks to HSA in the language the agency itself uses.

Insight 2: Regulation runs on a dual track of entity and product, and neither track can be skipped. Many manufacturers assume that once they hold a product registration certificate they are free to sell. The actual structure in Singapore is two parallel tracks:

• Product track: Class B/C/D devices must complete product registration (Part VII), while Class A devices go through product notification;
• Entity track: any entity that imports, wholesales or manufactures medical devices in Singapore must hold the corresponding Dealer’s Licence (Part VI).

If only the product track is completed and the entity holds no licence, the act of supplying the product is itself unlawful. This is the point we emphasise repeatedly in Southeast Asian projects, and it is the one most frequently overlooked by clients. The consequence is not a paperwork irregularity: supplying a registered product through an unlicensed entity can trigger enforcement at the customs or post-market stage, disrupt the launch timeline, and expose the local partner to penalties. A realistic project schedule therefore treats registration and licensing as two workstreams that start at the same time, not as sequential steps.

Insight 3: Regulatory functions are being further consolidated in 2026, and this deserves early attention. According to an official HSA announcement dated 9 September 2026, Singapore has proposed the Health Sciences Authority (Amendment) and Other Matters Bill, with the direction of consolidating health regulatory functions further under HSA in order to build a more coherent regulatory system. For companies that are already planning for the Singapore market, this is an institutional variable that needs continuous tracking: functional consolidation may bring subsequent adjustments to process entry points, system platforms and interface arrangements. (This item reflects an ongoing institutional reform; the specific provisions and effective date are subject to the Singapore Government Gazette and official HSA publications.) We recommend that clients treat this development as a standing agenda item in quarterly regulatory reviews rather than a one-off reading exercise.

4. Practical recommendations

• Confirm the regulator’s position at project initiation: Singapore has no two-tier local/central system of device regulation; HSA is the sole competent authority. Do not be misled by claims of multiple layers of agency approval.
• Schedule both tracks in parallel: start preparation of product registration and the Dealer’s Licence at the same time, rather than waiting for the registration certificate before applying for the licence.
• Establish a regulatory tracking mechanism: the GN series was updated several times within 2026 (GN-15 reaching R15 within a single year, GN-02 R8, GN-21 R7). We advise clients to check the version status on the HSA guidance documents page at least once per quarter.
• Make good use of official consultation channels: HSA offers pre-market consultation services (product development consultation at S$530, pre-submission consultation at S$210). For projects with uncertainty over classification or pathway, using a low-cost consultation to lock in the regulator’s position is far cheaper than reworking a dossier afterwards.

5. Verification checklist

• □ Confirm that the product falls within the definition of a medical device under the First Schedule of the Health Products Act
• □ Confirm that HSA is the competent authority and that no other parallel approval body exists
• □ Plan both the product registration track and the dealer licensing track simultaneously
• □ Check the current versions of GN-15, GN-02 and GN-21 on the HSA guidance documents page
• □ For projects with classification or pathway uncertainty, assess whether to apply for HSA pre-market consultation first

Regulatory information verified as of: 26 October 2026

Source level: Tier 1 (Health Products Act 2007, official HSA announcements), Tier 2 (HSA web pages and guidance documents)

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com